T. Rowe Price Investment Management, Inc. Erasca, Inc. Put Options Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
Others Institutions Holding ERAS
# of Institutions
162Shares Held
222MCall Options Held
20.6KPut Options Held
5.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.6MShares$27.5 Million1.95% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$19.8 Million5.36% of portfolio
-
Logos Global Management LP San Francisco, CA13MShares$15.9 Million3.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$15.5 Million0.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY12.3MShares$15 Million0.74% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $149M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...